High Plasma Glucose Raises Baby Heart-Defect Risk
By LabMedica International staff writers Posted on 27 Dec 2017 |

Image: Testing for blood glucose levels during early pregnancy to assess the risk of congenital heart disease (Photo courtesy of Paras Hospitals).
For many years, physicians have known that women with diabetes face an increased risk of giving birth to babies with heart defects and some studies have also suggested a link between nondiabetic mothers' blood sugar levels and babies' heart defect risk.
One challenge associated with conducting such studies was the fact that maternal blood glucose is not routinely measured in nondiabetic pregnant women. Instead, women typically receive an oral glucose tolerance test halfway through pregnancy to determine whether they have gestational diabetes, but this test is performed well after the fetal heart has formed.
A team of scientists mainly from Stanford University Medical Center (Stanford, CA, USA) studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers' prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. They also looked at the results of oral glucose tolerance tests (OGTT) performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.
After excluding women who had diabetes before pregnancy or who developed it during pregnancy, the results showed that the risk of giving birth to a child with a congenital heart defect was elevated by 8% for every increase of 10 mg/dL in blood glucose levels in the early stages of pregnancy. The mean early glucose value was 96 mg/dL (5.3 mmol/L) in pregnancies without congenital heart disease (CHD) versus 107 mg/dL (6.0 mmol/L) in pregnancies with CHD. The respective mean 1-hour OGTT values were 117 mg/dL (6.5 mmol/L) and 122 mg/dL (6.8 mmol/L).
The findings demonstrate that higher random plasma glucose values measured during early pregnancy correlate with increased risk for congenital heart disease in offspring of mothers who do not have diabetes. Furthermore, plasma glucose measured during early pregnancy was more associated with risk for congenital heart disease in offspring, compared with the OGTT which is often used to risk-stratify pregnancies for fetal-echocardiographic screening.
James R. Priest, MD, an assistant professor of pediatric cardiology and the senior author of the study, said, “Most women who have a child with congenital heart disease are not diabetic. We found that in women who don't already have diabetes or develop diabetes during pregnancy, we can still measure risk for having a child with congenital heart disease by looking at their glucose values during the first trimester of pregnancy.” The study was published on December 15, 2017, in The Journal of Pediatrics.
Related Links:
Stanford University Medical Center
One challenge associated with conducting such studies was the fact that maternal blood glucose is not routinely measured in nondiabetic pregnant women. Instead, women typically receive an oral glucose tolerance test halfway through pregnancy to determine whether they have gestational diabetes, but this test is performed well after the fetal heart has formed.
A team of scientists mainly from Stanford University Medical Center (Stanford, CA, USA) studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers' prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. They also looked at the results of oral glucose tolerance tests (OGTT) performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.
After excluding women who had diabetes before pregnancy or who developed it during pregnancy, the results showed that the risk of giving birth to a child with a congenital heart defect was elevated by 8% for every increase of 10 mg/dL in blood glucose levels in the early stages of pregnancy. The mean early glucose value was 96 mg/dL (5.3 mmol/L) in pregnancies without congenital heart disease (CHD) versus 107 mg/dL (6.0 mmol/L) in pregnancies with CHD. The respective mean 1-hour OGTT values were 117 mg/dL (6.5 mmol/L) and 122 mg/dL (6.8 mmol/L).
The findings demonstrate that higher random plasma glucose values measured during early pregnancy correlate with increased risk for congenital heart disease in offspring of mothers who do not have diabetes. Furthermore, plasma glucose measured during early pregnancy was more associated with risk for congenital heart disease in offspring, compared with the OGTT which is often used to risk-stratify pregnancies for fetal-echocardiographic screening.
James R. Priest, MD, an assistant professor of pediatric cardiology and the senior author of the study, said, “Most women who have a child with congenital heart disease are not diabetic. We found that in women who don't already have diabetes or develop diabetes during pregnancy, we can still measure risk for having a child with congenital heart disease by looking at their glucose values during the first trimester of pregnancy.” The study was published on December 15, 2017, in The Journal of Pediatrics.
Related Links:
Stanford University Medical Center
Latest Clinical Chem. News
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
- Simple Urine Test Could Detect Multiple Cancers at Early Stage
- Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules
- First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns
- Paper-Based Devices Outperform Existing Methods in Diagnosing Asymptomatic Malaria
- Simple Skin Test Could Revolutionize Diagnosis of Pediatric Eosinophilic Esophagitis
- Portable Diagnostic Tool Uses Bioluminescence to Detect Viruses at POC
- AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Channels
Molecular Diagnostics
view channel
DNA Methylation Signatures of Aging Could Help Assess Mortality Risk
Aging is associated with the progressive degeneration and loss of function across multiple physiological systems. Chronological age is the most common indicator of aging; however, there is significant... Read more
Molecular Diagnostics System Provides Lab-Quality Results at POC
Currently, there is a need for a comprehensive molecular diagnostics ecosystem that enables effective diagnostic stewardship, providing the diagnostic tools to offer the right tests, for the right patient,... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more